NAV

ORY-1001

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
ORY-1001
DrugBank Accession Number
DB16848
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 244.382
Monoisotopic: 244.193948781
Chemical Formula
C16H24N2
Synonyms
  • Iadademstat
External IDs
  • RG-6016
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
ORY-1001 dihydrochlorideG02YXY861Q1431326-61-2PWIVHEUJEJPRIZ-WCUAUJSVSA-N

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
XC0UT08SNJ
CAS number
1401966-39-9
InChI Key
VHNNYAVEBXCOSG-DISOXQEGSA-N
InChI
InChI=1S/C16H24N2/c17-14-8-6-12(7-9-14)11-18-16-10-15(16)13-4-2-1-3-5-13/h1-5,12,14-16,18H,6-11,17H2/t12?,14?,15-,16+/m0/s1
IUPAC Name
4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)cyclohexan-1-amine
SMILES
NC1CCC(CN[C@@H]2C[C@H]2C2=CC=CC=C2)CC1

References

General References
Not Available
ChemSpider
81368501

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentNeuroendocrine Carcinomas (NEC) / Small Cell Lung Cancer (SCLC)1
1Not Yet RecruitingTreatmentAcute Myeloid Leukemia / Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS)1
1RecruitingTreatmentRefractory Acute Myeloid Leukemia (AML) / Relapsed Acute Myelogenous Leukemia (AML)1
1, 2Not Yet RecruitingTreatmentExtensive-stage Small Cell Lung Cancer (SCLC) / Stage IV Lung Cancer AJCC v81

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0115 mg/mLALOGPS
logP2.47ALOGPS
logP2.39Chemaxon
logS-4.3ALOGPS
pKa (Strongest Basic)10.63Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area38.05 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity75.54 m3·mol-1Chemaxon
Polarizability30.06 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-f02407689cdcfda3dd78
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-002f-0590000000-53c9664fbad746f22ef8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0292-4930000000-769b916b86f5ac8d5d37
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0090000000-07afa0fc127b1983e35b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052p-8920000000-c5c56015141017f7c183
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01p6-3920000000-b99302955c16c95d7572
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at July 25, 2022 15:46 / Updated at April 27, 2024 13:34